Genetic Study Identifies Potential Therapeutic Targets for Aortic Aneurysm

A recent multi-omics study published in Artery Research has identified two genes, ADAMTS8 and IL6R, as promising candidates for future aortic aneurysm drug development. By integrating genetic, transcriptomic, and spatial data, researchers aimed to uncover the underlying mechanisms of the condition and pinpoint druggable targets.

Methodology and Findings

The research team utilized a two-sample Mendelian randomisation analysis, screening 5,900 potentially druggable genes. Through a series of rigorous evaluations—including protein quantitative trait locus analyses and Bayesian co-localisation—the study highlighted ADAMTS8 and IL6R as significant targets. Phenome-wide analysis further linked ADAMTS8 to blood pressure variations and IL6R to a reduced risk of allergies.

Additionally, the researchers explored potential mediators for the IL6R association, finding that coronary atherosclerosis and high-density lipoprotein levels may account for a small portion of the link to aortic aneurysm. An exploratory analysis also identified four existing compounds—cyclopenthiazide, primaquine, decitabine, and progesterone—that interact with these target genes.

Next Steps for Research

While these findings offer a new foundation for understanding aortic aneurysm, the study authors emphasize that the results are currently computational. The identified targets and compounds represent preliminary hypotheses rather than proven clinical treatments. Further experimental validation and clinical trials are required to confirm the biological relevance, safety, and therapeutic efficacy of these genetic targets in human patients.